EANS-Adhoc: LifeWatch announces joint development of new breakthrough test for its wireless cardiac monitoring platform (with document)

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

New Products/LifeWatch AG

24.02.2012

The testing technology will be deployed on LifeWatch wireless cardiac
monitors in coming months.

Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss
Exchange:LIFE), the leading wireless cardiac monitoring service
provider in the U.S., announced today the joint development of
additional Sympathetic and Parasympathetic testing with the ANSAR
Group.

For the first time in the wireless cardiac monitoring industry, the
treating physician will be able to measure individual parasympathetic
and sympathetic responses of their patient. This information will be
significant in providing additional clinical data for patients with
Atrial Fibrillation, Syncope (fainting), Congestive Heart Failure,
Cardiac Autonomic Neuropathy (associated with increased risk of
mortality and morbidity) and Hypertension. These conditions together
affect an estimated 99 million Americans1. An additional subset of
patients who could benefit from this test includes millions of
Americans who are currently prescribed Beta blockers.

"The Ansar test integrated with our ACT cardiac telemetry platform is
a very important technological advance", stated Dr. Yacov Geva,
Chairman and CEO of LifeWatch AG. "For the first time ever, a
physician will be provided with invaluable clinical information about
a patient's sympathetic and parasympathetic nervous system in a
comprehensive arrhythmia report via an outpatient cardiac monitoring
platform. The data generated from the Ansar test and LifeStar ACT
cardiac monitor will assist in guiding therapy. Physicians will be
able to diagnose vasovagal or neurocardiogenic syncope, orthostasis,
arrhythmia or palpitations caused by surges in the parasympathetic or
sympathetic tone with the LifeWatch ACT monitor. This has the
potential to improve patient outcomes, reduce medication loads,
hospitalizations, unnecessary deaths and overall healthcare costs. It
is an honor for LifeWatch to be able to empower physicians with this
capability."

The Ansar parasympathetic and sympathetic response monitoring test
allows for the differential diagnosis of three main causes of syncope
(neurogenic, vasovagal and cardiogenic), and other causes of
dizziness (including orthostasis and arrhythmia). These individual
measurements can be recorded preceding an arrhythmic event, which
will provide physicians with clear and precise documentation of the
causes of underlying syncope, dizziness, arrhythmia, chest pain, or
sleep disordered cardiac disturbances, etc., and aid the physician in
the differential diagnosis and guiding therapy.

The easy-to-use test utilizes a LifeStar ACT wireless cardiac monitor
enabling real-time viewing of the ECG before the patient is sent home
for continued arrhythmia monitoring. The Ansar test, which is
reimbursable, includes physiological parameters equivalent to a
head-up tilt table test, and has demonstrated higher rates of
specificity and sensitivity2. This test is encouraged by many of the
leading professional medical societies in the United States,
including the AHA, ADA, JDFI, AAN, AAFP, NIH. Published,
peer-reviewed, parasympathetic and sympathetic response testing data
shows how to optimize therapy for many difficult to treat conditions,
including Atrial Fibrillation, Heart Failure, Hypertension, Dizziness
(including syncope) and sleep disorders. This technology will be
available in the US in the following months.

Sources: 1. Circulation 2012, 125:e2-e220, 2. Am Heart J
1997;134:316-20.

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare
technology and solution company, specializing in advanced telehealth
systems and wireless remote patient monitoring services. LifeWatch
services cater to individuals, ranging from high-risk and chronically
ill patients, to consumers of health and wellness products. LifeWatch
has subsidiaries in the United States, the Netherlands, Japan, the
United Kingdom, Switzerland and Israel. LifeWatch AG is the parent
company of LifeWatch Services Inc., a leading US-based cardiac
monitoring service provider, and manufacturer of telecardiology
products. LifeWatch is also introducing a new program for Home Sleep
Testing of Obstructive Sleep Apnea (OSA) patients under the brand
name NiteWatch. For additional information, please visit
http://www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify
forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business
strategy, short term and long term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking
events and circumstances described may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward-looking statements. All forward-looking
statements are based only on data available to LifeWatch AG at the
time of the issue of this press release. LifeWatch AG does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/9HSfZYNF

Further inquiry note:
Sensus Investor and Public Relations GmbH, Zürich:
Tel+41 433665511 | Fax+41 43 366 55 12|Email lifewatch@sensus.ch

end of announcement euro adhoc
--------------------------------------------------------------------------------

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/9HSfZYNF

issuer: LifeWatch AG
Rundbuckstrasse 6
CH-8212 Neuhausen am Rheinfall
phone: +41 52 632 00 50
FAX: +41 52 632 00 51
mail: users@lifewatch.com
WWW: www.lifewatch.com
sector: Healthcare Providers
ISIN: CH0012815459
indexes: SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
SIX Swiss Exchange
language: English